Optimal Cost-Effective Go-No Go Decisions in Late-Stage Oncology Drug Development
Authors:
- Cong ChenCCCong Chen
- Robert A. BeckmanRBRobert A. Beckman
- 1 May 2009
- journal article
- Published by Taylor & Francis in Statistics in Biopharmaceutical Research
- Vol. 1 (2) , 159-169
Abstract
In late-stage oncology drug development, drug developers have to make two critical Go-No Go decisions. The first one is whether to proceed to the definitive Phase III investigation after a Phase II...Keywords
This publication has 13 references indexed in Scilit:
- A Bayesian approach for incorporating economic factors in sample size design for clinical trials of individual drugs and portfolios of drugsStatistics in Medicine, 2007
- Design Issues of Randomized Phase II Trials and a Proposal for Phase II Screening TrialsJournal of Clinical Oncology, 2005
- Assurance in clinical trial designPharmaceutical Statistics, 2005
- Timing of futility analyses for ‘proof of concept’ trialsStatistics in Medicine, 2005
- Bayesian Statistics and the Efficiency and Ethics of Clinical TrialsStatistical Science, 2004
- New designs for phase 2 clinical trialsBlood, 2003
- Clinical Trial Designs for the Early Clinical Development of Therapeutic Cancer VaccinesJournal of Clinical Oncology, 2001
- A Bayesian Decision Approach for Sample Size Determination in Phase II TrialsBiometrics, 2001
- Clinical Trial Designs for Cytostatic Agents: Are New Approaches Needed?Journal of Clinical Oncology, 2001
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989